SGLT2 inhibitors - a potential treatment for Alport syndrome

Clin Sci (Lond). 2020 Feb 28;134(4):379-388. doi: 10.1042/CS20191276.


Alport syndrome is a rare genetic disease that results in disordered basement membrane type IV collagen resulting in occular and auditory defects as well of progressive kidney disease. Although no 'cure' currently exists, therapeutic blockade of the renin-angiotensin-aldosterone system can slow the progression to end-stage kidney disease (ESKD). Clinical trials for treatments in preventing chronic kidney disease have largely been negative over the last two decades until recent trials have shown positive cardiovascular and renal outcomes of sodium-glucose co-transporter-2 (SGLT2) inhibitors in patients with diabetes mellitus. Although marketed as medications for Type 2 diabetes, SGLT2 inhibitors have been found to have additional properties that are nephroprotective which makes them a potential candidate for treatment for those with other forms of progressive kidney disease. This review discusses the evidence for the use of SGLT2 inhibitors as a potential treatment in Alport syndrome that may slow the progression of chronic kidney disease and prevent patients reaching ESKD.

Keywords: chronic kidney disease; renal glomerulus; renin-angiotensin system.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Glomerular Filtration Rate
  • Humans
  • Nephritis, Hereditary / drug therapy*
  • Nephritis, Hereditary / physiopathology
  • Protective Agents / therapeutic use
  • Sodium-Glucose Transporter 2 Inhibitors / adverse effects
  • Sodium-Glucose Transporter 2 Inhibitors / therapeutic use*


  • Protective Agents
  • Sodium-Glucose Transporter 2 Inhibitors